Edition:
United Kingdom

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

14.55USD
5:58pm GMT
Change (% chg)

$0.43 (+3.05%)
Prev Close
$14.12
Open
$14.24
Day's High
$15.19
Day's Low
$14.24
Volume
24,998
Avg. Vol
37,612
52-wk High
$15.19
52-wk Low
$4.63

Latest Key Developments (Source: Significant Developments)

Savara Inc - Development Award Raised to $6.7 Mln - Sec Filing
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Savara Inc ::SAVARA- ON NOV 28 ENTERED INTO AMENDMENT EFFECTIVE SEPT 30,TO RESEARCH PROGRAM AWARD LETTER AGREEMENT BETWEEN CO, CYSTIC FIBROSIS FOUNDATION THERAPEUTICS.SAVARA INC - UNDER AMENDMENT, AMOUNT OF DEVELOPMENT AWARD AVAILABLE TO SAVARA WAS INCREASED BY $5 MILLION TO AN AGGREGATE OF $6.7 MILLION - SEC FILING.  Full Article

Savara ‍Received $5 Mln Award For Development Of Aerovanc​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Savara Inc ::SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​.  Full Article

Savara posts Q3 loss per share $0.28
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Savara Inc :Savara reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.28.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Anticipating complete enrollment in molgradex phase 3 impala study in q1 2018​.Initiating phase 2A study of Molgradex for treatment of NTM in early 2018​.Expecting top-line results from aironite phase 2 indie study in h1 2018​.Research and development expenses were $5.0 million for three-months ended September 30, 2017, compared with $2.1 million for Q3 of 2016​.  Full Article

SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Savara Inc ::SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAVARA INC - ‍PRICES UNDERWRITTEN PUBLIC OFFERING OF 5.25 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $7.85 PER SHARE​.  Full Article

Savara announces proposed public offering of common stock
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Savara Inc :Savara announces proposed public offering of common stock.  Full Article

Savara reports completion of enrollment
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Savara Inc ::Savara reports completion of enrollment in phase 2 clinical trial of aironite for the treatment of hfpef.Savara Inc - ‍expects that top-line results from indie-hfpef study will be available in first half of 2018​.  Full Article

Mast Therapeutics provides business update
Monday, 26 Sep 2016 

Mast Therapeutics Inc : Mast Therapeutics provides business update . Company has begun to wind down its vepoloxamer programs in sickle cell disease and heart failure . Company is planning to initiate a process to evaluate partnership opportunities for its assets . Co to make $10 million prepayment on debt facility triggered by recently announced results of phase 3 study of vepoloxamer in early Oct 2016 . Expects wind down activities will be completed in Q4 of 2016 .Company estimates that its operating expenses for 2017 will be in range of $9 to $10 million.  Full Article

Mast Therapeutics Q2 loss per share $0.05
Tuesday, 9 Aug 2016 

Mast Therapeutics Inc : Q2 loss per share $0.05 . Mast therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Mast Therapeutics receives notice of allowance of composition of matter patent application
Wednesday, 8 Jun 2016 

Mast Therapeutics Inc : Mast Therapeutics receives notice of allowance of composition of matter patent application covering vepoloxamer . Patent is expected to expire no earlier than July 2035 . Also has filed corresponding patent applications that will allow co to seek similar patent protection for vepoloxamer in key markets .Notice of allowance concludes substantive examination of patent application.  Full Article

Mast Therapeutics says updated timing for data from Vepoloxamer study
Monday, 6 Jun 2016 

Mast Therapeutics Inc : Updated anticipated timing for announcement of top-line data from phase 3 clinical study of Vepoloxamer in patients with sickle cell disease .Delay does not reflect on quality or integrity of results or conduct of study.  Full Article

BRIEF-Savara Inc - Development Award Raised to $6.7 Mln - Sec Filing

* SAVARA- ON NOV 28 ENTERED INTO AMENDMENT EFFECTIVE SEPT 30,TO RESEARCH PROGRAM AWARD LETTER AGREEMENT BETWEEN CO, CYSTIC FIBROSIS FOUNDATION THERAPEUTICS